Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
538.00
+5.00 (0.94%)
Aug 21, 2026, 4:08 PM HKT

HKG:6990 Stock Forecast

Stock Price Forecast

According to 19 analysts polled by S&P Global, HKG:6990 stock has a consensus rating of "Strong Buy" and an average price target of $612.59. The average 1-year stock price forecast is 13.86% higher than the current stock price, while the lowest is $520.00 (-3.35%) and the highest is $765.30 (+42.25%).

Price Target: $612.59 (+13.86%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$520.00$612.59$622.00$765.30
Change-3.35%+13.86%+15.61%+42.25%

Analyst Ratings

The average analyst rating for HKG:6990 stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy161615151516
Buy333333
Hold000000
Sell000000
Strong Sell000000
Total191918181819

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
SPDB
No rating
SPDB
Buy
Maintains
$611.60$624.00
BuyMaintains$611.60$624.00+15.99%Aug 21, 2026
Unknown Analyst
BOCOM International Holdings Company
No rating
BOCOM International Holdings Company
Buy
Maintains
$642.00
BuyMaintains$642.00+19.33%Aug 20, 2026
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$550.00$630.00
BuyMaintains$550.00$630.00+17.10%Aug 20, 2026
Unknown Analyst
Huatai Securities
No rating
Huatai Securities
Buy
Maintains
$765.30
BuyMaintains$765.30+42.25%Aug 20, 2026
CMB International Securities
CMB International Securities
Buy
Maintains
$507.11$642.29
BuyMaintains$507.11$642.29+19.38%Aug 19, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
2.52B
from 2.06B
Increased by 22.33%
Revenue Next Year
4.46B
from 2.52B
Increased by 77.00%
EPS This Year
-0.09
from -1.04
EPS Next Year
3.55
from -0.09
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
32.32M803.93M1.54B1.93B2.06B2.52B
Revenue Growth
-2,387.26%91.62%25.48%6.46%22.33%
Gross Profit
9.25M526.80M759.19M1.27B1.48B1.89B
Gross Margin
28.62%65.53%49.28%65.89%71.86%75.09%
Operating Income
-795.24M-393.95M-453.70M-279.22M-419.57M-427.02M
Net Income
-889.80M-616.10M-574.13M-266.77M-381.97M44.45M
EPS
-----1.04-0.09
Free Cash Flow
--174.83M-438.58M-410.80M-182.09M32.81M
No. Analysts
-----18
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High2.9B
Avg2.5B
Low2.0B

Revenue Growth

Revenue Growth202620272028
High
42.6%
Avg
22.3%
Low
-1.6%

EPS Forecast

EPS202620272028
High0.53
Avg-0.09
Low-0.70

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-